FDA Drug Shortage Crisis: India Energy Crunch Threatens 40% of US Generic Supply

The Perfect Storm Brewing in Global Pharma Supply The United States faces an unprecedented pharmaceutical supply chain crisis as India's escalating energy shortage threatens to cripple 40% of the global Active Pharmaceutical Ingredient (API) supply. With natural gas prices surging and power grid instability plaguing India's pharmaceutical manufacturing hubs, the FDA's drug shortage list—already containing over 100 medications—is poised for dramatic expansion. India dominates global generic drug production, supplying roughly 20% of all generic medications to the US market and nearly 40% of generic and over-the-counter drugs consumed by Americans. The country's pharmaceutical exports totaled $24.4 billion in fiscal 2023, with the US representing the largest single market. Now, this critical supply line faces severe disruption as energy-intensive API production grinds to a halt. Energy Crisis Hits Pharma Giants Hard FairStock.ai's analysis reveals that major Indian pharmaceutical companies are experiencing significant revenue exposure to the energy crisis. Sun Pharmaceutical Industries (SUNPHARMA.NSE), India's largest drugmaker with a market cap of ₹4.17 trillion and quarterly revenue of ₹15,521 crores, faces moderate risk with ₹2,328 crores in revenue at risk from energy disruptions. The company trades at 34.34 times earnings with an ROE of 14.07%, but its FairStock Intelligence Score of 55 suggests vulnerability to operational headwinds. Dr. Reddy's Laboratories (DRREDDY.NSE) shows similar exposure patterns, with ₹1,313 crores in quarterly revenue potentially impacted by gas supply constraints. Aurobindo Pharma (AUROPHARMA.NSE) and Lupin (LUPIN.NSE) each face over ₹1,000 crores in revenue at risk, while Cipla (CIPLA.NSE) confronts ₹1,061 crores in potential disruption. The energy crisis particularly impacts manufacturers of critical intermediates. Companies producing morpholine—essential for respiratory medications—face critical risk as 85% of global supply dep...